Petauri PACT Executive Briefings - 3-Minute Market Insights

Send us Fan Mail The IQVIA Institute recently reported that there were 15,501 Illegal Online Pharmacies, or I-O-P’s, collectively selling approximately 85 million illegal prescriptions, with an estimated value of $34 billion dollars. At the time of the study, these IOP’s were actively marketing 70% (5,085) of the 7,310 legally prescribed medicines dispensed to patients in the USA. Need more inform...

Send us Fan Mail Antimicrobial Resistance Could Surpass Cancer as the Leading Cause of Death by 2050.  Antimicrobial Resistance is globally recognized as one of the greatest health threats of the 21st century , and yet... we hardly hear anything about it. It’s directly responsible for 1.27 million deaths in 2019 and contributing to 4.95 million deaths overall. Social distancing reduced that number...

Send us Fan Mail Balancing Early Detection and Incidental Findings in Lung Cancer Screening Lung cancer is the leading cause of cancer-related deaths globally. While the 5-year survival rate for locally advanced lung cancer is under 5%, early-stage diagnosis can elevate this rate to as high as 60%. Mortality risk factors include age, smoking history, environmental conditions, and social determinan...

Send us Fan Mail Welcome to our updated 3-minute Executive Briefing, where we’ve rebranded our program under our new Petauri name. As you are familiar, The Kinetix Group partnered with Petauri Health, a purpose-built pharmaceutical commercialization services platform based in New York City, to expand TKG’s capabilities and enhance the resources and expertise available to our clients. Over the last...

Send us Fan Mail The topic for this week’s @The Kinetix Group PACT Executive Briefing is “The FACT Standards for Immune Effector Cells.” These accrediting standards were developed by the Foundation for the Accreditation of Cellular Therapy (FACT), using a consensus of experts to promote quality medical and laboratory practice across the field of immune effector cell therapy. Immune Effector Cells...

Send us Fan Mail Medication Adherence for Patients with Severe Mental Illness. Adherence to prescribed medication regimens improves outcomes for patients with severe mental illness, such as schizophrenia, bipolar disorders, and major depressive disorder. Psychiatric disorders are a significant public health problem: schizophrenia affects about 23 million people worldwide, bipolar disorders affect...

Send us Fan Mail Introduction to Gene-Editing Therapy: CRISPR CRISPR is a relatively new medical advancement that was inspired by the natural defense mechanism found in some microbes, such as bacteria. To protect themselves against invaders like viruses, these microbes capture snippets of the intruder’s DNA and store them away as segments called CRISPRs, or Clustered Regularly Interspersed Short P...

Send us Fan Mail Introduction to Targeted Therapies: CAR T-cell Therapy  T-cell Transfer Therapy is a special type of immunotherapy that takes a person’s own T-cells (a type of immune cell), adds specific antigens to the T-cells that can identify the cancer cells,  and puts them back into the person’s body. Cancer cells express unique antigens (signaling proteins). T-cells are programmed in the la...

Send us Fan Mail Provider Insights on the Impact of 340B Pricing . We frequently get asked for insights on how the 340B Drug Pricing Program may... or may not... be impacting the prescribing choices of participating covered entities. The Health Resources and Services Administration (HRSA) administers this federal program which is intended to help safety-net providers carry out their missions to se...

Send us Fan Mail Today’s topic is the The Federal NOPAIN Act. The Federal “Non-Opioids Prevent Addiction In the Nation Act” (or, the “NOPAIN Act”), Senate bill S.586, was signed into law in December 2022. It takes effect this coming January as part of the Centers for Medicare and Medicaid Services 2025 OPPS proposed rule.  The NOPAIN Act directs CMS to reimburse hospital and surgical centers separ...

Send us Fan Mail The High-Value Pharmacy Enterprise Framework. The High-Value Pharmacy Enterprise Framework is a collection of evidence-based and expert recommended best practices designed to enhance health system pharmacy operations by ensuring safe, effective, and patient-centered medication management throughout the health-system pharmacy enterprise. It is gaining in popularity due to the many...

Send us Fan Mail Introduction to Targeted Therapies: Monoclonal Antibodies Targeted Therapy is the foundation of Precision Medicine. Targeted therapy is a type of personalized treatment that targets specific proteins that control how cells grow, divide, and spread.  Antibodies are produced naturally by our body and help the immune system recognize cells that cause disease, such as bacteria and vir...

Send us Fan Mail All 50 states now allow pharmacists and physicians to enter into Collaborative Practice Agreements (CPAs) in which one or more pharmacists establish a formal relationship with a prescriber, in which the prescriber can delegate specific tasks to a pharmacist under negotiated conditions, which would not otherwise be permitted under the pharmacist’s normal scope of practice Although...

Send us Fan Mail When a physician prescribes an expensive specialty medication for a patient, the traditional distribution process was for the provider to purchase the medication, administer it to the patient, and then bill the insurance company for the drug. This “buy-and-bill” process has been utilized for many years.  In recent years, and to help control costs, third-party payers have mandated...

Send us Fan Mail Laboratory Benefit Managers have emerged over the past decade to fill the need to manage complex and expensive laboratory testing for payers. They have become the new Precision Medicine Gatekeepers.  Results from over 14 billion diagnostic tests are estimated to influence 70% of today’s clinical decisions. It’s estimated that there is both overutilization of testing in approximate...

Send us Fan Mail The term therapeutic inertia describes the failure of health care providers to initiate or intensify therapy when it is clearly indicated by established guidelines. The term has largely been applied to the management of blood pressure, blood sugar, and cholesterol, by primary care physicians who recognize the need for their patients to control these conditions but fail to act suff...

Send us Fan Mail Since 2016, 13 states have passed Drug Price Transparency Laws focused on enabling state policymakers to understand opaque drug pricing and payment systems to formulate policy solutions to high prices, while also creating the data infrastructure to realize those policy solutions.  Most of these state programs require reporting from manufacturers when they increase the Wholesale Ac...

Send us Fan Mail Today's topic is the CMS Prior Authorization Final Rule   On January 17th, 2024, CMS published the CMS Interoperability and Prior Authorization Final Rule, to improve the electronic exchange of health care data as well as to streamline prior authorization processes. This final rule also adds a new measure for merit-based incentive payment system or MIPS eligible clinicians. B...

Send us Fan Mail Today’s topic is the Federal No Surprises Act. The Federal No Surprises Act is intended to protect consumers from unexpected medical bills that occur when a patient unknowingly receives medical services from physicians and other providers who are outside of their health insurance network; in other words, healthcare providers who are not “in network”.  The law protects consumers sp...

Send us Fan Mail Welcome to our new and revised market insights podcast format, where we have renamed our program the TKG PACT Executive Briefing. The new format will be condensed into 3-minute episodes of market insights, where we highlight one of healthcare’s critical market access issues, policies, challenges, or trends. We hope you enjoy this new “3-Minute Market Insights” format and hope that...

Send us Fan Mail Telehealth Policy Gaps: Challenges with Remote Prescribing On May 11th, the Public Health Emergency (PHE) and some of the provisions that supported the explosive growth of telehealth, will expire, leaving telehealth providers scrambling to address some of the challenges of proving remote care. My special guest in this episode is Dori Martini, Vice President of Operations and Regul...

Send us Fan Mail Circling the Wagons… to Solve Real Problems in Neurology It is estimated that globally, one in six people are affected by a health issue that includes some form of a neurological disorder. Within the United States, as many as 100 million people are having some kind of an issue related to a neurological disorder. Add to that the explosion of breakthrough new therapies for challengi...

Send us Fan Mail "Period Poverty"... a Taboo Topic? Unfortunately, there are some issues in healthcare that seem to get ignored, or simply don’t get discussed appropriately, and today’s topic is one of these challenging issues.   In many circles, menstruation is a topic that is difficult to discuss openly, which complicates the challenges of period poverty. Today we explore the challenge...

Send us Fan Mail NCCN Policy & Advocacy Priorities Supporting high quality cancer care through the NCCN Guidelines is a strategic pillar for the NCCN. Alyssa Schatz is the Senior Director of Policy & Advocacy at the National Comprehensive Cancer Network. She shares the current strategic priorities for her team in this week’s episode.

Send us Fan Mail Musical Chairs... Improving Infusion Therapy “Musical Chairs”… how are we managing infusion center operations amid the financial and staffing woes of a healthcare system exhausted from nearly 3 years of a roller coaster ride due to the pandemic? Our guests for this episode are Christine Mann, Chief Operating Officer and Director of the DENT Infusion Center, DENT Neurologic Institu...